title: Biologic Therapy for Psoriatic Arthritis.
abstract: Biologic medications, therapeutic proteins that inhibit or modulate proinflammatory immune cells and cytokines, have significantly altered clinicians' ability to effectively treat psoriatic arthritis (PsA). The first widely used biologics have been those targeting tumor necrosis factor alpha. Five agents (etanercept, infliximab, adalimumab, golimumab, and certolizumab) have shown significant benefit in all clinical domains of PsA as well as inhibiting progressive joint destruction. Treatment strategies such as treating PsA early in the disease course, treating to target and tight control, use of background methotrexate to reduce immunogenicity, and various cost-saving strategies are all being tested with biologic medicines for PsA.
authors.affiliation: Clinical Rheumatology Research, Swedish Medical Center, 601 Broadway, Seattle, WA 98122, USA; University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195, USA. Electronic address: pmease@philipmease.com.
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Mease
mesh_terms: D015535:Arthritis, Psoriatic / Q000628:therapy*; D001691:Biological Therapy / Q000379:methods*; D006801:Humans
keywords: Biologics; IL-12–23 inhibition; IL-17 inhibition; IL-23 inhibition; Psoriasis; Psoriatic arthritis; TNF inhibition